Japan Medical Isotope

Japan Medical Isotope (JMI) is a specialized company dedicated to establishing a stable domestic supply of medical radioisotopes in Japan. The company focuses primarily on the production of Molybdenum-99 (Mo-99), the parent isotope of Technetium-99m (Tc-99m), which is essential for millions of diagnostic imaging procedures annually. JMI utilizes a non-fission neutron activation method (n, gamma) using domestic nuclear reactors to produce isotopes without generating high-level radioactive waste or requiring highly enriched uranium. By securing a local production chain, the company aims to mitigate the risks associated with Japan's historical 100% reliance on imported isotopes from aging overseas reactors. JMI operates as a collaborative venture involving major industrial and pharmaceutical partners to integrate isotope production, processing, and distribution.